Proteome Reshaped: Billions of Spectra, New Discoveries
The established human proteome, once considered largely charted territory, is proving to be far more expansive and cryptic than presumed. We’ve embarked on an ambitious, almost dystopian-scale data crunch, constructing the Human non-HLA and HLA PeptideAtlas builds from an astonishing 3.5 billion MS/MS spectra across nearly 300 ProteomeXchange datasets. This isn’t mere bioinformatics; it’s a relentless digital excavation using tools like MSFragger, designed to unearth signals from previously invisible microproteins and peptideins. Each spectral whisper, a fragmented echo from within a cell, represents a potential new data point, a missing piece in the grand biological blueprint.
Ensuring the veracity of these nascent identifications demands a statistical gauntlet. Our Trans-Proteomic Pipeline (TPP) functions as a hyper-vigilant gatekeeper, utilizing tools like PeptideProphet and iProphet to meticulously validate every potential peptide-spectrum match. Crucially, we estimate the false discovery rate (FDR) of non-canonical ORF (ncORF) detections through a cunning target-decoy entrapment approach. This involves introducing “fake” protein sequences to trick the system, allowing us to quantify errors with chilling precision. This scientific “truth serum” ensures that when a new microprotein is detected, it’s a confirmed entity, challenging existing dogma.
Decoding the Unseen: Rigor & Revelation
Discovery is exhilarating, but validation is where the real work, and the real intrigue, lies. Every identified ncORF peptide undergoes a manual inspection process so stringent it rivals a top-secret security clearance. Our experts scrutinize peptide-spectrum matches for “excellent” evidence, demanding near-complete b and y ion series coverage and the absence of anomalous peaks, a process where a single errant ion can condemn a candidate. This meticulous forensics, part of the ongoing GENCODE project, separates the truly novel from the statistical mirage, leaving no spectral anomaly unaccounted for.
The complexity deepens when exploring the cellular immune landscape via HLA immunopeptidomics. Here, a unique challenge arises as HLA-presented peptides often defy conventional enzymatic digestion. Our approach involves “no-enzyme” searches across hundreds of HLA-enriched datasets to capture these irregular fragments, effectively sweeping the forgotten corners of the proteome. We then categorize these peptides with surgical precision, distinguishing those from established proteins versus the enigmatic ncORFs. This meticulous sorting, paired with profiling ncORF expression in diverse tissues, including cancer datasets, begins to map their potential functional terrain.
Moving beyond spectral evidence, we seek direct observational proof of translation. Ribosome profiling (Ribo-seq) data, visualized through platforms like GWIPS-viz and RiboCrypt, provides undeniable “footprints” of actively translating ribosomes on ncORFs. This direct evidence is crucial for assigning each ncORF a “tier” of validation, from Tier 1A for robustly supported candidates to Tier 5 for purely computational predictions. Furthermore, analyzing evolutionary conservation through ORBL scores reveals many ncORFs are highly conserved across mammalian species, suggesting their biological roles are not accidental but profoundly functional.
The Unseen Architects: Unmasking Function
The ultimate validation for these microproteins is demonstrating their tangible impact. We deployed a suite of genetic warfare tools, including CRISPR screens, siRNA knockdowns, and overexpression studies, targeting specific ncORFs like c10riboseqorf92 and OLMALINC in a vast array of cancer cell lines. Pooled knockout screens, where hundreds of barcoded cell lines are grown together and systematically targeted, allowed us to quantify the precise survival consequences of eliminating these cryptic elements. By correlating these viability profiles with genome-wide perturbation data from projects like DepMap, we began to uncover phenotypic similarities, proving their active role in shaping cellular fate.
To fully grasp the ripple effects of microprotein manipulation, we harnessed multi-omics. Bulk RNA-seq revealed systemic transcriptional shifts following ncORF knockdown, while single-cell RNA-seq provided unparalleled resolution into cellular heterogeneity, pinpointing specific populations affected. Advanced computational analyses, such as weighted gene co-expression network analysis (WGCNA), identified gene modules intimately linked to ncORF activity, revealing their involvement in fundamental biological processes. These comprehensive functional validations confirm that microproteins are not biological ephemera, but rather unseen architects, subtly dictating crucial cellular decisions.
Scientific Facts Worth Knowing
- •💡 The Human PeptideAtlas, through its latest builds, processes billions of MS/MS spectra to identify novel peptides, expanding the detectable proteome far beyond previously cataloged proteins.
- •💡 False discovery rates (FDRs) for ncORF detections are meticulously estimated using target-decoy entrapment, a standard community technique, ensuring high confidence in novel identifications.
- •💡 Ribosome profiling (Ribo-seq) provides direct evidence of translation, with ‘excellent’ verification requiring four sequential, in-frame Ribo-seq peaks within an ncORF’s first 100 nucleotides.
- •💡 The ORBL conservation score quantifies evolutionary constraint by measuring the phylogenetic branch length of conserved species, suggesting functional significance for many ncORFs.
- •💡 CRISPR screens and multi-omics analyses reveal that microproteins influence critical cellular processes, opening new avenues for therapeutic intervention in diseases like cancer.
